Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ignyta Names Senior VP, Chemistry & Manufacturing

This article was originally published in Scrip

Executive Summary

Ignyta, Inc., a precision oncology biotechnology company, has appointed Dr Valerie Harding to the newly created role of senior vice-president, chemistry, manufacturing, and controls. Harding joins Ignyta from Pfizer, where she held many roles including vice-president of product differentiation, vice-president of drug product design and vice-president of pharmaceutical development. Prior to Pfizer, Harding spent three years as a scientist and team leader at Boots and Company, preceded by three years as a tutor and researcher at the University of Nottingham's School of Pharmacy. Harding holds a Ph.D. in Pharmaceutical Microbiology from the University of Nottingham and a B.S. in Pharmacy from the University of London.

You may also be interested in...

VC View: Deal-Making During A Pandemic And 2021 Expectations

In the latest instalment of VC Playbook, In Vivo gets to know Arix Bioscience, a relatively young venture capital firm that went public in 2016. Arix has “has many similarities yet some key differences from a typical venture capital firm,” says the management team.

Snapshot: August Highlights

A selection of articles you might have missed from August 2020, including exclusive interviews with industry leaders and a review of financing trends.

‘Translators’ Will Form The Next Generation Of Biopharma Leaders

Rabia Khan, managing director of discovery sciences at Sensyne Health, talks to In Vivo about pairing biology with technology in the most effective way, managing COVID-19 challenges and what the future leaders of biopharma might look like.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts